Status: Recruiting
Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma
This study is conducted to evaluate the efficacy, prognosis, adverse effects, and factors for predicting therapeutic effects and clinical prognosis of combined therapy of hepatic artery infusion chemotherapy (HAIC), tyrosine kinase inhibitor/ anti-VEGF antibody, and anti-PD-1/ PD-L1 antibody for advanced hepatocellular carcinoma which initially unsuitable for the radical therapy, including resection, transplantation, or ablation. Factors are collected in preoperative routine blood examination, preoperative radiological imaging and pathological examination.
Participants needed: 300
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Ze-yang Ding, MDUpdated: Mar 25, 2025Locations: 2
Eligibility criteria
Age ≥ 18 years old; [+9]
Prior invasive malignancy within 2 years except for noninvasive malignancies suc...